Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Akero Therapeutics, Inc. (AKRO)  
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 90,746,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $0 - $0
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Akero Therapeutics is a clinical-stage company developing treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. NASH is a severe form of nonalcoholic fatty liver disease characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, cancer and death. Co.'s primary product candidate, efruxifermin, is an analog of fibroblast growth factor 21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 200,000 400,000 1,000,000
Total Buy Value $0 $8,787,921 $18,387,921 $32,465,426
Total People Bought 0 1 1 1
Total Buy Transactions 0 3 4 8
Total Shares Sold 233,406 448,979 1,264,329 1,736,886
Total Sell Value $12,156,162 $21,106,418 $51,685,100 $65,762,394
Total People Sold 8 8 8 8
Total Sell Transactions 27 40 89 131
End Date 2025-05-22 2025-02-18 2024-08-20 2023-08-21

   
Records found: 498
  Page 1 of 20  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Gangloff Scott A. Chief Technology Officer   •       –      –    2025-08-15 4 OE $19.62 $51,012 D/D 2,600 26,351     -
   Henderson Jane   –       •      –    2025-08-12 4 S $47.46 $142,371 D/D (3,000) 9,398     -
   Henderson Jane   –       •      –    2025-08-12 4 OE $7.01 $21,027 D/D 3,000 12,398     -
   Young Jonathan Chief Operating Officer   •       –      –    2025-08-12 4 AS $47.72 $597,326 D/D (12,500) 197,484     -
   Young Jonathan Chief Operating Officer   •       –      –    2025-08-12 4 OE $21.10 $263,750 D/D 12,500 209,984     -
   Cheng Andrew President and CEO   •       •      –    2025-08-11 4 AS $48.07 $1,457,596 D/D (30,000) 490,757     -
   Rolph Timothy Chief Scientific Officer   •       –      –    2025-08-05 4 AS $49.07 $616,299 D/D (12,500) 167,124     -
   Rolph Timothy Chief Scientific Officer   •       –      –    2025-08-05 4 OE $21.09 $263,625 D/D 12,500 179,624     -
   Yale Catriona Chief Development Officer   •       –      –    2025-07-16 4 AS $52.87 $529,467 D/D (10,000) 91,488     -
   Yale Catriona Chief Development Officer   •       –      –    2025-07-16 4 OE $19.87 $198,700 D/D 10,000 101,488     -
   Cheng Andrew President and CEO   •       •      –    2025-07-10 4 AS $50.57 $1,534,895 D/D (30,000) 520,757     -
   Rolph Timothy Chief Scientific Officer   •       –      –    2025-07-07 4 AS $50.93 $638,661 D/D (12,500) 167,124     -
   Rolph Timothy Chief Scientific Officer   •       –      –    2025-07-07 4 OE $21.09 $263,625 D/D 12,500 179,624     -
   Lamy Patrick Senior VP, Commercial Strategy   •       –      –    2025-07-01 4 AS $52.88 $105,760 D/D (2,000) 29,891     -
   Yale Catriona Chief Development Officer   •       –      –    2025-06-30 4 A $23.87 $21,243 D/D 890 91,488     -
   White William Richard Chief Financial Officer   •       –      –    2025-06-30 4 A $23.87 $21,243 D/D 890 58,411     -
   Gangloff Scott A. Chief Technology Officer   •       –      –    2025-06-30 4 A $23.87 $7,137 D/D 299 23,751     -
   Lamy Patrick Senior VP, Commercial Strategy   •       –      –    2025-06-30 4 A $23.87 $4,607 D/D 193 31,891     -
   Cheng Andrew President and CEO   •       •      –    2025-06-30 4 A $23.87 $21,243 D/D 890 550,757     -
   Rolph Timothy Chief Scientific Officer   •       –      –    2025-06-30 4 A $23.87 $21,243 D/D 890 167,124     -
   Young Jonathan Chief Operating Officer   •       –      –    2025-06-30 4 A $23.87 $21,243 D/D 890 197,484     -
   Lamy Patrick Senior VP, Commercial Strategy   •       –      –    2025-06-20 4 S $54.59 $47,766 D/D (875) 31,698     -
   White William Richard Chief Financial Officer   •       –      –    2025-06-18 4 S $54.84 $89,609 D/D (1,634) 57,521     -
   Yale Catriona Chief Development Officer   •       –      –    2025-06-18 4 S $54.84 $89,554 D/D (1,633) 90,598     -
   Young Jonathan Chief Operating Officer   •       –      –    2025-06-18 4 S $54.84 $79,683 D/D (1,453) 196,594     -
  498 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 20
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2025 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us